Faster pacing with a pacemaker for right heart failure with leaky tricuspid valve
Tests a faster heart rate through left bundle branch pacing in right heart failure.
Plain-language title generated from the registry record
Registry title: Accelerated LBBP for Patients With RHF and Severe TR
Key facts
- Where
- Nanchang and Shanghai, ChinaSee the 3 sites
Where in China
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNo longer taking part
- Shanghai Geriatric Medical CenterShanghai, ChinaNo longer taking part
- Shanghai Zhongshan HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07470047
- Record updated
- 13 March 2026
- Original description
This study is a prospective, single-arm, target value clinical trial. We plan to prospectively enroll and follow 24 patients across three centers nationwide who have a low baseline heart rate (HR ≤ 60 bpm), meet the indication for permanent pacemaker implantation, and have right-sided heart failure with severe or greater tricuspid regurgitation. All patients will undergo pacemaker implantation using left bundle branch pacing (LBBP), and the pacing rate will be uniformly increased to 90 bpm (reduced to 80-85 bpm in case of intolerance). Patients will be followed for 6 months to evaluate the effects of heart-rate increase on hemodynamics, heart failure symptoms, and physical function in patients with right-sided heart failure.Read full original descriptionShow less
Accelerated Left Branch Bundle Pacing in the Treatment of Right Heart Failure With Severe Tricuspid Regurgitation: A Prospective, Multicenter, Single-Arm Target Value Clinical Trial
This study is a prospective, single-arm, target value clinical trial. We plan to prospectively enroll and follow 24 patients across three centers nationwide who have a low baseline heart rate (HR ≤ 60 bpm), meet the indication for permanent pacemaker implantation, and have right-sided heart failure with severe or greater tricuspid regurgitation. All patients will undergo pacemaker implantation using left bundle branch pacing (LBBP), and the pacing rate will be uniformly increased to 90 bpm (reduced to 80-85 bpm in case of intolerance). Patients will be followed for 6 months to evaluate the effects of heart-rate increase on hemodynamics, heart failure symptoms, and physical function in patients with right-sided heart failure.
Inclusion: Mean resting heart rate ≤ 65 beats/min (based on a resting electrocardiogram); Clinically confirmed right-sided heart failure, requiring ≥2 diuretic units to fully control edema, or having persistent grade ≥1 edema despite diuretic therapy; Diuretic unit definition: expressed as the number of daily doses at the standard oral dose. For example, the standard units for furosemide, torasemide, and spironolactone are 20 mg/day, 10 mg/day, and 20 mg/day, respectively. If a patient takes furosemide 20 mg twice daily and spironolactone 20 mg once daily, the total diuretic units equal 3; Echocardiography shows severe or greater tricuspid regurgitation; With/without an indication for permanent pacemaker implantation; Is able to understand the purpose of the trial, voluntarily participates and signs written informed consent, and is willing to complete follow-up visits as required by the protocol.
Exclusion: Prior implantation of a cardiac pacemaker; Participation in another drug or medical device clinical trial that has not yet been completed; Mean pulmonary artery pressure (mPAP) > 35 mmHg measured by right heart catheterization at a pacing rate of 60 bpm; Current use of heart rate-lowering medications, such as beta-blockers, digoxin, ivabradine, etc; Left ventricular ejection fraction (LVEF) < 50% or left ventricular end-diastolic diameter (LVEDD) > 56 mm as measured by echocardiography; Moderate or greater left-sided valvular regurgitation or stenosis; Untreated hypothyroidism; Deemed unsuitable for participation in this clinical trial by the investigator.